- Home
- EXAS vs GLOB Comparison
EXAS vs GLOB Comparison
Compare EXAS & GLOB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXAS
- GLOB
- Stock Information
- Founded
- EXAS 1995
- GLOB 2003
- Country
- EXAS United States
- GLOB Luxembourg
- Employees
- EXAS N/A
- GLOB N/A
- Industry
- EXAS Medical Specialities
- GLOB EDP Services
- Sector
- EXAS Health Care
- GLOB Technology
- Exchange
- EXAS Nasdaq
- GLOB Nasdaq
- Market Cap
- EXAS 10.7B
- GLOB 4.7B
- IPO Year
- EXAS N/A
- GLOB 2014
- Fundamental
- Price
- EXAS $53.17
- GLOB $90.87
- Analyst Decision
- EXAS Strong Buy
- GLOB Buy
- Analyst Count
- EXAS 20
- GLOB 16
- Target Price
- EXAS $70.16
- GLOB $174.94
- AVG Volume (30 Days)
- EXAS 2.8M
- GLOB 1.1M
- Earning Date
- EXAS 07-30-2025
- GLOB 08-14-2025
- Dividend Yield
- EXAS N/A
- GLOB N/A
- EPS Growth
- EXAS N/A
- GLOB N/A
- EPS
- EXAS N/A
- GLOB 3.38
- Revenue
- EXAS $2,828,128,000.00
- GLOB $2,455,696,000.00
- Revenue This Year
- EXAS $14.58
- GLOB $4.36
- Revenue Next Year
- EXAS $12.75
- GLOB $6.03
- P/E Ratio
- EXAS N/A
- GLOB $26.96
- Revenue Growth
- EXAS 11.57
- GLOB 11.90
- 52 Week Low
- EXAS $39.97
- GLOB $86.02
- 52 Week High
- EXAS $72.83
- GLOB $238.32
- Technical
- Relative Strength Index (RSI)
- EXAS 42.14
- GLOB 39.45
- Support Level
- EXAS $50.09
- GLOB $88.10
- Resistance Level
- EXAS $53.20
- GLOB $92.20
- Average True Range (ATR)
- EXAS 1.78
- GLOB 3.18
- MACD
- EXAS -0.53
- GLOB 0.27
- Stochastic Oscillator
- EXAS 24.40
- GLOB 25.86
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
About GLOB Globant S.A.
Globant is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2003 in Argentina but is currently headquartered in Luxembourg and primarily serves clients in the US and Latin America. Globant's client base is relatively concentrated in the media and entertainment and financial services industries.